Compare Allegion PLC (ALLE) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allegion PLC vs ClearPoint Neuro Inc — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while ClearPoint Neuro Inc trades at $17.19 (market cap $524.82M). The key difference: Allegion PLC is far larger — about 22.4× ClearPoint Neuro Inc's market cap, and Allegion PLC pays a 1.55% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| ALLE | CLPT | |
|---|---|---|
Market Cap | $11.74B | $524.82M |
Sector | Industrials | Health |
52-Week High | $179.77 | $29.60 |
52-Week Low | $125.65 | $8.66 |
Enterprise Value | $13.46B | $552.81M |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
ClearPoint Neuro (CLPT) trades at $17.50, down 2.13% on the day, with a bullish technical signal from moving averages despite recent earnings misses. The company reported record Q1 2026 revenue of $41M with 43% growth but continues to post significant net losses, reflected in a negative net income margin of -71.57%. Recent FDA clearance for its Velocity Alpha surgical drill and a new partnership in South Korea highlight ongoing business development efforts.
The investment case hinges on CLPT's positioning in the gene therapy enabling space, with 100% analyst buy ratings supporting long-term growth potential. However, persistent cash burn, regulatory dependencies on partner therapies like AMT-130, and execution risks present substantial challenges. Investors face high volatility given the speculative nature of its growth trajectory against current profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
